In addition to scalability, another opportunity is presented by clinical feasibility and performance. For example, lymphodepletion conditioning, which is a must for ex vivo-engineered CAR-T cells, is ...
Gilead Sciences has become the latest pharma to strengthen its in vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics. Integrating Interius into ...
Intellia Therapeutics is pioneering in vivo CRISPR gene editing, aiming for groundbreaking therapies, with NTLA-2001 showing promising results in ATTR amyloidosis, potentially achieving blockbuster ...
Please provide your email address to receive an email when new articles are posted on . ORLANDO — An in vivo chimeric antigen receptor T-cell therapy administered without lymphodepletion exhibited ...
SANTA MONICA, Calif. & PHILADELPHIA--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results